About us

Leading the charge against neurodegenerative diseases through groundbreaking gene therapy innovation

About us
Our dedication to research and commitment to neurological health place us at the forefront of science and medicine, with a clear mission: to improve the lives of those facing these devastating conditions.

At Tetraneuron, we believe in a future where neurodegenerative diseases no longer signify relentless suffering and decline. Instead, we envision personalized and effective therapies that bring hope and enhance quality of life. This dream is what drives us to work tirelessly every day.
Our mission
Our mission is to revolutionize the landscape of neurodegenerative diseases by providing safe and effective gene therapies targeting disorders like Alzheimer's and other aging-related neurodegenerative conditions. We're dedicated to scientific excellence and ethical standards at every stage of our journey.
Our Experience
At Tetraneuron, our team consists of scientists and biotechnology experts who have dedicated their careers to researching and developing gene therapies for neurodegenerative diseases. With our expertise in neuroscience and technology, we approach complex medical challenges in innovative ways.

Our history

2023

New strategic alliances in Parkinson and aging

2022

Pre-IND meeting with the FDA

2021

Beginning of the preclinical regulatory phase

2020

Methode validation of TET-101

2019

Analysis of biological processes modulated by E2F4DN

2018

Validation of the Leading Compound

2017

Validation of the Leading Compound

2016

Identification of the Leading Compound

2015

Validation of the therapeutical target E2F4DN

2014

Beginning of the proof of concept

2013

Identification of the therapeutical target E2F4

2012

Tetraneuron was founded

Tetraneuron es una empresa biotecnológica española de terapia génica centrada en las enfermedades cerebrales y neurodegenerativas

Con sede en Madrid y Valencia, Tetraneuron nace como spin-off del Instituto Cajal, perteneciente al Consejo Superior de Investigaciones Científicas (CSIC)

Comprometidos con la excelencia científica y la ética en cada paso del camino.

Our team

Team

Strategic Advisors

Team

Strategic Advisors

Loading...

José M. Frade. PhD

Scientific Director and co-Founder

Álvaro Pascual-Leone. MD.PhD

Scientific Board Member

Teodoro del Ser. MD. PhD

Scientific Board Member

David Mor

Board Member

Mari Carmen Álvarez. PhD

Managing Director

Mar Municio. PhD

R&D Director

Noelia López Sánchez. PhD

Technical Director

Cristina Sánchez Puelles. PhD

Senior Researcher

Morgan Ramón Landrau

Researcher

Alberto Garrido

Laboratory Technician

Vanesa Cano

Laboratory Technician

Irene Camacho

PhD. Student

Loading...

Marika Russo. PhD

Strategic Advisor

Alonso Fernández Nistal, PhD

Strategic Advisor

Ángel Lucio Pereira

Strategic Advisor

Collaborating Institutions

A new path for neurodegenerative diseases

Contact

VALENCIA
BIOHUB VLC
Travesía s/n 15 E Base 5,
46024 Valencia

MADRID
C/ Velázquez, 154 – Pta Baja Izda A , 28002 Madrid